1. Disclaimer
The information provided in this report is intended solely for educational and professional reference purposes and is not a substitute for medical advice, diagnosis, or treatment.
We do not guarantee the accuracy, currency or completeness of information regarding medications or medical products, and official sources should be verified before making any decisions. By using this blog, you agree to assume personal responsibility for relying on the information provided.
Clinical decisions must always be based on the most recent approved prescribing information, local regulatory guidance, and the judgment of qualified healthcare professionals.
2. Summary
Beclo® Nasal Spray is an intranasal corticosteroid formulation containing beclomethasone dipropionate, indicated for the prevention and treatment of allergic and non-allergic rhinitis and for reducing recurrence of nasal polyps following surgical removal. Its therapeutic effect is mediated through potent local anti-inflammatory activity within the nasal mucosa, with minimal systemic exposure when administered at recommended doses. The product referenced reflects an older dosing schedule, which differs from many contemporary international regimens.
3. Brand Name
Beclo® Nasal Spray
4. Category
- Intranasal corticosteroid
- Anti-inflammatory / Anti-allergic agent
5. Active Ingredient
Beclomethasone dipropionate (as monohydrate) Each metered dose delivers 50 micrograms, equivalent to 42 micrograms of anhydrous beclomethasone dipropionate.
6. Pharmaceutical Form & Strength
- Pharmaceutical form: Metered-dose aqueous nasal spray
- Strength: 50 mcg per actuation
- Pack size: 20 mL bottle providing approximately 200 metered doses
7. Manufacturer & Marketing Authorization Holder
AMOUN Pharmaceutical Co. S.A.E. El-Obour City, Cairo, Egypt
8. Mechanism of Action
Beclomethasone dipropionate is a synthetic corticosteroid that is converted locally to its active metabolite, beclomethasone-17-monopropionate. This metabolite binds to glucocorticoid receptors within nasal mucosal cells, leading to modulation of gene transcription and suppression of inflammatory pathways. The drug reduces mediator release, inhibits inflammatory cell infiltration, decreases capillary permeability, and produces local vasoconstriction, resulting in reduced mucosal edema and symptom relief.
9. Spectrum of Activity
Not applicable. Beclo® Nasal Spray has no antimicrobial activity. Its therapeutic spectrum is limited to inflammatory and allergic conditions of the nasal mucosa.
10. Pharmacokinetics
- Absorption: Minimal systemic absorption following intranasal administration
- Bioavailability: Very low due to extensive first-pass hepatic metabolism of the swallowed fraction
- Metabolism: Rapid hepatic metabolism to inactive metabolites
- Elimination: Primarily via feces; minor renal excretion
- Onset of action: Partial symptom improvement within 24–48 hours; maximum benefit after several days to 1–2 weeks of continuous use
11. Indications
Beclo® Nasal Spray is indicated for:
Prophylaxis and treatment of:
- Seasonal allergic rhinitis
- Perennial allergic rhinitis
- Vasomotor (non-allergic) rhinitis
Prevention of recurrence of nasal polyps following surgical removal
Recurrence may occur after discontinuation, depending on disease severity.
12. Administration
Route: Intranasal use only
Dosage (according to provided product information):
- Adults and adolescents ≥12 years: Initial: 2 sprays in each nostril twice daily Maintenance: Lowest effective dose (e.g., 1 spray in each nostril up to three times daily)
- Children 6–12 years: 1 spray in each nostril up to three times daily
Dose adjustment should be based on clinical response.
13. Method of Preparation
No preparation is required. The product is supplied as a ready-to-use metered-dose nasal spray. Shake well before use and prime the pump prior to first administration or after prolonged non-use.
14. Contraindications
- Hypersensitivity to beclomethasone dipropionate or any component of the formulation
15. Warnings & Precautions
- Prolonged use of higher-than-recommended doses may result in systemic corticosteroid effects, including adrenal suppression
- Caution is required when transferring patients from systemic corticosteroids
- Local nasal infections should be appropriately treated but are not an absolute contraindication
- Use with caution following recent nasal surgery or trauma until healing is complete
- Periodic examination of the nasal mucosa is recommended during long-term therapy
16. Drug Interactions
- Clinically significant interactions are unlikely due to low systemic exposure
- Strong CYP3A4 inhibitors (e.g., ritonavir, ketoconazole) may increase systemic corticosteroid effects with prolonged use
17. Side Effects
Common:
- Nasal irritation or dryness
- Sneezing
- Unpleasant taste or smell
- Mild epistaxis
Uncommon/Rare:
- Nasal septal perforation
- Local Candida infection
- Systemic corticosteroid effects with excessive or prolonged dosing
18. Use in Special Populations
- Pediatrics: Use recommended doses; monitor growth with prolonged therapy
- Pregnancy: Use only if benefit outweighs potential risk
- Lactation: Minimal systemic exposure; use with caution
- Elderly: No specific dose adjustment required
19. Storage Conditions
- Store below 30°C
- Protect from heat and direct sunlight
- Do not freeze
- Keep out of reach of children
20. Additional Sections
Patient Counseling Information:
Regular daily use is required for optimal efficacy. The spray is not intended for immediate relief of acute nasal congestion.
21. Frequently Asked Questions (FAQ)
Q1: Is Beclo® Nasal Spray a bronchodilator? A: No. It is a corticosteroid with local anti-inflammatory activity.
Q2: How long can it be used? A: Long-term use is acceptable under medical supervision at the lowest effective dose.
Q3: Can it be stopped suddenly? A: Yes, but symptoms may recur if the underlying condition persists.
22. References
- Manufacturer product leaflet (AMOUN Pharmaceutical Co.)
- ARIA (Allergic Rhinitis and its Impact on Asthma) guidelines
- British National Formulary (BNF): Beclomethasone nasal preparations
- Published pharmacokinetic and safety data on intranasal corticosteroids